PURITY & TESTING

Peptide Purity: What 99% on a COA Does and Does Not Mean

Learn the difference between peptide purity, identity and milligrams per vial, with a fictional COA example and questions to ask about laboratory testing.

A peptide purity percentage does not, by itself, tell you how many milligrams of peptide are in a vial. Identity, purity, and content are separate analytical questions. A 2023 report on peptide reference standards describes multiple tests and an assigned peptide content for lyophilized vials, rather than treating one chromatographic percentage as a complete product assessment. USP-authored reference-standard research

When you see “99% purity,” ask 99% of what, measured how, in which sample? Then look separately for the amount, identity, and any other tests relevant to the claim. Keep the impressive number in context while you evaluate the rest of the documentation.

Four questions to keep separate

Use four headings in your notes: identity, purity, content, and other quality testing. Under each heading, record the stated method, result, units, and sample identifier. Leave a blank where the document does not supply an answer.

Use this organization before comparing suppliers. It directs attention to the evidence supplied, rather than rewarding whichever document uses the most confident language.

HPLC purity versus peptide content

High-performance liquid chromatography, or HPLC, is a separation technique. FDA’s biotechnology inspection guide describes its use in characterization and purity assessment. A chromatogram represents the detector response under the method’s conditions; interpreting it requires the method and the basis used to report a result. FDA description of HPLC

For this explainer, consider a report that explicitly defines purity as the main peak’s area divided by the summed area of the included peaks. Read that as an area-percentage result. Do not silently reinterpret its denominator as total vial mass.

Hypothetical chromatogram: Suppose the included peaks have areas of 990 and 10 arbitrary units. The main peak accounts for 990 ÷ 1,000 × 100 = 99% of the included area. This is an invented calculation, not a real laboratory finding.

Nothing in those two peak-area numbers specifies the total mass in a vial. The calculation contains neither a vial-mass measurement nor a calibrated amount result. You cannot obtain a defensible “milligrams per vial” answer from that arithmetic alone.

Ask the laboratory whether the report includes a separate quantitative assay. Request the units and reporting basis, and check whether the result refers to the submitted sample, a bulk material, or a finished vial.

Why water, salts, and other components matter

Peptide purity by mass can require accounting for components beyond peptide-related chromatographic peaks. In an angiotensin II reference-material study, researchers used complementary quantitative approaches and measured the trifluoroacetic acid counter-ion, which represented nearly 25% of mass in that particular material. This is a specific analytical example, not a statement about every peptide vial. Primary reference-material study

NIST researchers have also examined mass balance, corrected amino-acid analysis, elemental analysis, and quantitative nuclear magnetic resonance for assigning peptide purity by mass. The measurement problem is broader than choosing the tallest peak. NIST angiotensin I research

When a report says “purity,” ask whether it means chromatographic area percentage, mass fraction, or another defined measurement. Copy the definition exactly into your notes. Do not compare two percentages until you know they use comparable definitions.

Avoid treating the presence of a counter-ion as a standalone verdict that a sample is defective. Investigate how the material is specified, what basis was used for quantitation, and whether the result matches that specification. The purpose is to understand the measurement, not to turn an unfamiliar chemical term into an accusation.

Does a high purity result confirm identity?

Ask for the identification result separately. A purity calculation should not do the work of a molecular identification.

Peptide reference-standard research describes complementary identity methods and structural questions that can require more than a mass match. That distinction is why “main peak: 99%” should not be treated as a complete molecular description. Reference-standard characterization

For an example involving actual peptide naming, read TB-500, thymosin beta-4 and CJC-1295: why names matter. Apply the same habit to a COA: record the exact identified material, including any relevant modification, then compare it with the product claim.

Purity is not sterility or an endotoxin result

FDA discusses sterility assurance and testing for microbial contamination and pyrogens or bacterial endotoxins as distinct quality considerations for relevant drug products. A peptide chromatography result is not a replacement for those tests. FDA production and process-control questions

Bacterial endotoxins are associated with gram-negative bacteria and can remain after bacterial death. FDA’s technical discussion also explains that the product can interfere with endotoxin testing, making method suitability important. These are general scientific principles from a historical technical guide, not a current testing protocol or universal acceptance limit. FDA endotoxin background

Read every test as its own line item. If a report supplies an endotoxin result, retain the units, limit, and method. If it supplies a sterility result, record that separately. Do not convert “not tested” into “passed,” or assume an unnamed test is included in a general marketing phrase.

Do not use this article to declare a research material suitable for injection. Bring questions about a medical product’s appropriateness to a qualified clinician and pharmacist.

A fictional COA, interpreted carefully

The following record is invented for teaching. It does not represent a real laboratory, vendor, sample, or quality finding.

For these fictional numbers, 8.0 mg is 80% of the 10 mg label claim. The 99.0% area-purity entry and the 8.0 mg content entry answer different questions; the first cannot be used to erase the second. No real product was measured to generate this example.

Do not label the imaginary sample a regulatory failure from the arithmetic alone. Ask about the specification, validated method, uncertainty, and sampling context before making a compliance judgment. Use the example to practice describing what a document actually says.

How much confidence should you place in a laboratory result?

FDA’s Q2(R2) guidance addresses validation of analytical procedures. The relevant question is whether a procedure is suitable for its intended analytical purpose, not simply whether an instrument was used. FDA Q2(R2)

Ask for an explanation of how the result was obtained. For a quantitative result, request the reference standard, calibration approach, reporting units, and any stated uncertainty or acceptance criteria. Ask how the method distinguishes the target from relevant interfering components.

Use a clear request such as: “Please identify the method used for the reported milligrams per vial and explain whether that number is measured content or the nominal amount supplied by the customer.” This avoids arguing over a number before establishing what it represents.

When comparing laboratories, resist sorting results to two decimal places without understanding method differences. Ask whether the results are comparable before interpreting a small numerical difference as a meaningful quality advantage.

Verify the document and its connection to the sample

Use this practical sequence when reviewing a COA:

1. Obtain the complete report, including footnotes and attachments referenced in it.
2. Match report identifiers, material name, sample ID, and stated lot across the pages.
3. Check the report through the laboratory’s own verification channel where one exists.
4. Ask who selected and submitted the sample, and how it relates to the lot being discussed.
5. Identify whether the tested item was raw material or a finished product.
6. Separate measured entries from information supplied by the customer.
7. Record missing tests as missing, without making an unsupported allegation.

Treat authenticity and relevance as two questions. First investigate whether the laboratory issued the document. Then examine what the document actually establishes about the material under consideration.

Preserve the report and the date you checked it. If a newer report appears, compare identifiers before replacing the old record. Use the COA reading guide for the broader document-review workflow.

Questions to send to a supplier or laboratory

Use these prompts selectively rather than sending a generic demand for “all testing”:

• What is the exact material and form identified on this report?
• Does the purity percentage mean chromatographic area or purity by mass?
• Is the amount per vial measured, and which method produced that number?
• Which entries were supplied by the customer rather than measured by the laboratory?
• Was the sample a finished vial or bulk material?
• What evidence connects the tested sample to this lot?
• Which additional tests were performed, and where are their individual results?
• How can the report number be verified directly?

Keep the response alongside the document. If an answer remains unclear, describe the uncertainty precisely instead of converting it into either a recommendation or an accusation. Apply the same standard to every supplier, including affiliated businesses.

Frequently asked questions

Does 99% purity mean a 10 mg vial contains 9.9 mg?

Not from an area-purity percentage alone. That calculation requires a relevant mass basis and quantitative information that the percentage itself does not supply. In the fictional chromatogram above, only detector areas were given.

Is 99.9% always better than 99.0%?

Do not decide from those numbers alone. Compare what was measured, the analytical method, the sample, the uncertainty, and the other quality attributes relevant to your question.

Does a COA establish FDA approval?

A laboratory report is not an FDA approval decision. FDA also states that compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness, or quality before marketing. FDA compounding overview

What if no amount-per-vial result is supplied?

Request it, including the method and units. Do not relabel the nominal vial size as a measured assay. If the result is unavailable, mark content unverified in your review.

Can a high-purity blend be assumed to work better?

Keep product testing separate from evidence of benefit. Read peptide blend research to evaluate whether the combination itself was studied.

Sources and editorial scope

Prepared with AI assistance on September 13, 2026. This article uses selected analytical research and official guidance. Published abstracts and available reference-standard excerpts were checked; a comprehensive full-text appraisal of the analytical papers was not completed. Official FDA pages were inspected. No real COA or vendor sample was tested.

labels identify documented information or explicit arithmetic, not certification of any product. The fictional report, questions, and worksheets are original educational material.

References: USP reference-standard research; Angiotensin II purity assignment; NIST peptide measurement research; FDA biotechnology inspection guide; FDA process-control questions; FDA endotoxin background; FDA Q2(R2); FDA compounding overview.